Product Code: 3033
Direct-to-Consumer (DTC) Genetic Testing Market is anticipated to gain substantial growth between 2023 and 2032, primarily due to the rising disposable incomes, especially in emerging countries. For instance, a report claims that between 2019 and 2030, the annual disposable income, ranging from USD 45,000 to USD 100,000 will increase by more than 5.5% per year.
Besides, the increasing awareness about the detection and diagnosis of hereditary and rare genetic diseases among the general populace across the globe will also fuel the market demand. Furthermore, experts in the field believe that genetic testing will become a regular part of clinical care, which will also favor the market in the foreseeable future.
In addition, the key providers in the DTC genetic testing industry are also seeking to strengthen their foothold in the market by investing in R&D projects and engaging in meaningful mergers, acquisitions, and joint ventures. To cite an instance, in December 2022, it was reported that researchers at the BC Cancer Research Institute have advanced genetic testing procedures, which allows better identification of those genes that can eventually lead to cancer.
Overall, the DTC genetic testing market has been segmented in terms of test, technology, distribution channel, and region.
Based on the test, the nutrigenomic testing segment is anticipated to grow significantly over the next ten years, and by 2032 this segment should grow at over 13.5% CAGR. Nutrigenomic testing boasts of advantages such as identifying locations of metabolic weakness, understanding the safety profile and toxicity of micro and macronutrients, and preventing diet diseases.
On the basis of technology, the market growth is likely to be characterized by the whole genome sequencing segment. The segmental growth can be credited to the increasing cases of rare genetic disorders. Besides, the technology is also being widely accepted as it provides a base-by-base view and a high resolution of the genome, apart from accessing large data and identifying potential causes, which will further fuel the market demand through 2032.
In terms of the distribution channel, the online platform segment is anticipated to grow at a robust rate through 2023-2032, owing to the increasing number of online websites which facilitate direct-to-consumer genetic testing.
In the regional context, the North America DTC genetic testing market is anticipated to be valued at more than USD 4.9 billion by 2032 end. The regional market growth can be attributed to the increasing usage of DTC genetic tests in the region since they have reduced the mortality rates of patients.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Industry coverage
- 1.2 Market scope & definitions
- 1.3 Base estimates & working
- 1.4 Forecast parameters
- 1.5 COVID-19 impact analysis at global level
- 1.6 Data validation
- 1.7 Data sources
- 1.7.1 Primary
- 1.7.2 Secondary
- 1.7.2.1 Paid sources
- 1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
- 2.1 Direct-to-Consumer (DTC) genetic testing industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Test type trends
- 2.1.3 Technology trends
- 2.1.4 Distribution channel trends
- 2.1.5 Regional trends
Chapter 3 Direct-to-Consumer (DTC) Genetic Testing Industry Insights
- 3.1 Industry landscape, 2018 - 2032
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising public awareness regarding DTC genetic tests
- 3.2.1.2 Rise in disposable income in emerging economies
- 3.2.1.3 Increasing demand for personalized DTC genetic services in developed countries
- 3.2.1.4 Growing incidences of genetic disorders globally
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of DTC kits
- 3.2.2.2 Defects in the DTC testing
- 3.2.2.3 Data privacy concerns associated with DTC genetic testing
- 3.3 Growth potential analysis
- 3.3.1 By test type
- 3.3.2 By technology
- 3.3.3 By distribution channel
- 3.4 COVID-19 impact analysis
- 3.5 Technology landscape
- 3.6 Future market trends
- 3.7 Regulatory landscape
- 3.7.1 U.S.
- 3.7.2 Europe
- 3.7.2.1 Germany
- 3.7.2.2 UK
- 3.7.2.3 France
- 3.7.2.4 Spain
- 3.7.2.5 Italy
- 3.7.3 Asia Pacific
- 3.7.3.1 China
- 3.7.3.2 Japan
- 3.7.3.3 India
- 3.7.3.4 Australia
- 3.7.4 Latin America
- 3.7.5 MEA
- 3.8 Value chain analysis
- 3.9 Data privacy concerns
- 3.10 DTC genetic testing - pricing analysis, 2021
- 3.11 Reimbursement scenario
- 3.12 Porter's analysis
- 3.13 PESTEL analysis
Chapter 4 Competitive Landscape, 2021
- 4.1 Introduction
- 4.2 Company matrix analysis, 2021
- 4.3 Company market share analysis, 2021
- 4.4 Strategy dashboard, 2021
Chapter 5 Direct-to-Consumer (DTC) Genetic Testing Market, By Test Type
- 5.1 Key segment trends
- 5.2 Carrier testing
- 5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million & Units)
- 5.3 Predictive testing
- 5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million & Units)
- 5.4 Ancestry & relationship testing
- 5.4.1 Market estimates and forecast, 2018 - 2032 (USD Million & Units)
- 5.5 Nutrigenomic testing
- 5.5.1 Market estimates and forecast, 2018 - 2032 (USD Million & Units)
- 5.6 Skincare testing
- 5.6.1 Market estimates and forecast, 2018 - 2032 (USD Million & Units)
- 5.7 Others
- 5.7.1 Market estimates and forecast, 2018 - 2032 (USD Million & Units)
Chapter 6 Direct-to-Consumer (DTC) Genetic Testing Market, By Technology
- 6.1 Key segment trends
- 6.2 Targeted analysis
- 6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.3 Single nucleotide polymorphism (SNP) chips
- 6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 6.4 Whole genome sequencing [WGS]
- 6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Direct-to-Consumer (DTC) Genetic Testing Market, By Distribution Channel
- 7.1 Key segment trends
- 7.2 Online platforms
- 7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
- 7.3 Over-the-counter
- 7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Direct-to-Consumer (DTC) Genetic Testing Market, By Region
- 8.1 Key regional trends
- 8.2 North America
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Thailand
- 8.4.7 Singapore
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Chile
- 8.6 Middle East & Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Turkey
Chapter 9 Company Profiles
- 9.1 23andMe, Inc.
- 9.2 Ancestry
- 9.3 Counsyl
- 9.4 Gene by Gene
- 9.5 Easy DNA
- 9.6 Full Genome Corporation Inc.
- 9.7 Helix OpCo LLC
- 9.8 Karmagenes SA
- 9.9 Living DNA Ltd.
- 9.10 Mapmygenome
- 9.11 Identigene
- 9.12 Pathway genomics
- 9.13 Genesis Healthcare Co.
- 9.14 MyHeritage
- 9.15 The SkinDNA Company Pty Ltd
- 9.16 Ambry Genetics
- 9.17 Blueprint Genetics Oy
- 9.18 DNA Genotek Inc.
- 9.19 Dante Lab
- 9.20 DNA Diagnostic Center
- 9.21 HomeDNA